Novartis in Society Integrated Report2023
Annual Report 2023 and US Securities&Exchange Commission Form 20-F 2023
Other reporting documents
Investor relations
策略和位置
定位,定位
Animal research(PDF0.2MB) Clinical study transparency(PDF0.2MB) PDF0.2MB 后期访问(PDF0.1MB) Pre-Approval Access to Novartis Products through MAPs(PDF0.3MB) 可回收Clinical Trials(PDF0.1MB) PDF0.2MB Novartis Commitment to Diversity in Clinical Trials Novartis Position on Investigator Initiated Trials(IIT)和Investigator Initiated Research(IIR)(PDF 0.2MB)
编码,策略和指南
Novartis Third Party Code v.1.0(PDF0.6MB) * Novartis Third Party Code v.2.0(PDF0.3MB) ** Novartis Third Party Code v.3.0(PDF0.4MB) *** PDF0.5MB的Novartis Minium Information Security Controls for Suppliers 不受影响的采购订单不受影响的0.1兆PDF